Symmetric signal transduction and negative allosteric modulation of heterodimeric mGlu1/5 receptors.


Journal

Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217

Informations de publication

Date de publication:
01 06 2021
Historique:
received: 17 04 2020
revised: 09 11 2020
accepted: 01 12 2020
pubmed: 7 12 2020
medline: 12 1 2022
entrez: 6 12 2020
Statut: ppublish

Résumé

For a long time metabotropic glutamate receptors (mGluRs) were thought to regulate neuronal functions as obligatory homodimers. Recent reports, however, indicate the existence of heterodimers between group-II and -III mGluRs in the brain, which differ from the homodimers in their signal transduction and sensitivity to negative allosteric modulators (NAMs). Whether the group-I mGluRs, mGlu1 and mGlu5, form functional heterodimers in the brain is still a matter of debate. We now show that mGlu1 and mGlu5 co-purify from brain membranes and hippocampal tissue and co-localize in cultured hippocampal neurons. Complementation assays with mutants deficient in agonist-binding or G protein-coupling reveal that mGlu1/5 heterodimers are functional in heterologous cells and transfected cultured hippocampal neurons. In contrast to heterodimers between group-II and -III mGluRs, mGlu1/5 receptors exhibit a symmetric signal transduction, with both protomers activating G proteins to a similar extent. NAMs of either protomer in mGlu1/5 receptors partially inhibit signaling, showing that both protomers need to be able to reach an active conformation for full receptor activity. Complete heterodimer inhibition is observed when both protomers are locked in their inactive state by a NAM. In summary, our data show that mGlu1/5 heterodimers exhibit a symmetric signal transduction and thus intermediate signaling efficacy and kinetic properties. Our data support the existence of mGlu1/5 heterodimers in neurons and highlight differences in the signaling transduction of heterodimeric mGluRs that influence allosteric modulation.

Identifiants

pubmed: 33279506
pii: S0028-3908(20)30494-9
doi: 10.1016/j.neuropharm.2020.108426
pii:
doi:

Substances chimiques

Grm5 protein, mouse 0
Receptor, Metabotropic Glutamate 5 0
Receptors, Metabotropic Glutamate 0
metabotropic glutamate receptor type 1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108426

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Ruth C Werthmann (RC)

Department of Biomedicine, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland.

Manuel Tzouros (M)

Roche Pharmaceutical Research and Early Development, Discovery Neuroscience, Neuroscience and Rare Diseases (NRD) (LL, CD, CF), Pharmaceutical Sciences, Biomarkers, Bioinformatics and Omics & Pathology (MT, JL, AA), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.

Jens Lamerz (J)

Roche Pharmaceutical Research and Early Development, Discovery Neuroscience, Neuroscience and Rare Diseases (NRD) (LL, CD, CF), Pharmaceutical Sciences, Biomarkers, Bioinformatics and Omics & Pathology (MT, JL, AA), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.

Angélique Augustin (A)

Roche Pharmaceutical Research and Early Development, Discovery Neuroscience, Neuroscience and Rare Diseases (NRD) (LL, CD, CF), Pharmaceutical Sciences, Biomarkers, Bioinformatics and Omics & Pathology (MT, JL, AA), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.

Thorsten Fritzius (T)

Department of Biomedicine, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland.

Luca Trovò (L)

Department of Biomedicine, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland.

Michal Stawarski (M)

Department of Biomedicine, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland.

Adi Raveh (A)

Department of Biomedicine, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland.

Catherine Diener (C)

Roche Pharmaceutical Research and Early Development, Discovery Neuroscience, Neuroscience and Rare Diseases (NRD) (LL, CD, CF), Pharmaceutical Sciences, Biomarkers, Bioinformatics and Omics & Pathology (MT, JL, AA), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.

Christophe Fischer (C)

Roche Pharmaceutical Research and Early Development, Discovery Neuroscience, Neuroscience and Rare Diseases (NRD) (LL, CD, CF), Pharmaceutical Sciences, Biomarkers, Bioinformatics and Omics & Pathology (MT, JL, AA), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland.

Martin Gassmann (M)

Department of Biomedicine, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland.

Lothar Lindemann (L)

Roche Pharmaceutical Research and Early Development, Discovery Neuroscience, Neuroscience and Rare Diseases (NRD) (LL, CD, CF), Pharmaceutical Sciences, Biomarkers, Bioinformatics and Omics & Pathology (MT, JL, AA), Roche Innovation Center Basel, Grenzacherstrasse 124, 4070, Basel, Switzerland. Electronic address: lothar.lindemann@roche.com.

Bernhard Bettler (B)

Department of Biomedicine, University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland. Electronic address: bernhard.bettler@unibas.ch.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH